Systematic review and network meta?analysis: efficacy of licensed drugs for abdominal bloating in irritable bowel syndrome with constipation
نویسندگان
چکیده
Background Although bloating is a highly prevalent and troublesome symptom in irritable bowel syndrome with constipation (IBS-C), treatment empirical no specific guidelines for its management. Aim To conduct pairwise network meta-analysis, using frequentist approach, of Food Drug Administration-licensed drugs IBS-C comparing their efficacy abdominal as endpoint. Methods We searched the medical literature through December 2020 to identify randomised controlled trials (RCTs) IBS-C, reported dichotomous assessment. Efficacy each drug was pooled relative risk (RR) 95% confidence intervals (CIs) summarise effect comparison tested. Treatments were ranked according P-score. Results identified 13 eligible RCTs, containing 10 091 patients. Linaclotide 290 µg o.d., lubiprostone 8 b.d., tenapanor 50 mg b.d. tegaserod 6 all superior placebo patients both meta-analyses. demonstrated greatest improvement meta-analysis (RR failure achieve an = 0.78; CI 0.74-0.83, number needed treat 7, P-score 0.97). Indirect revealed significant differences between individual drugs. Conclusions found licensed be bloating. appeared most efficacious at relieving Further research assess long-term these agents better understand precise mechanism improving
منابع مشابه
Bloating in irritable bowel syndrome
AIM The purpose of this study was to describe the occurrence of self report bloating and related factors in patients with irritable bowel syndrome (IBS). BACKGROUND Bloating symptoms are common in patients with IBS and have significant impact on normal daily function. PATIENTS AND METHODS This study was a community-based cross-sectional survey that conducted using a valid questionnaire base...
متن کاملEffects of baseline abdominal pain and bloating on response to lubiprostone in patients with irritable bowel syndrome with constipation
BACKGROUND Lubiprostone (8 μg b.d.) received US Food and Drug Administration (FDA) approval in 2008 for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) in women aged ≥18 years. In 2012, the FDA issued new guidance for IBS-C clinical trials, recommending a composite endpoint incorporating both abdominal pain and stool frequency. AIM In a post hoc analysis, similar cr...
متن کاملLinaclotide for irritable bowel syndrome with constipation: a review
2015 Irritable bowel syndrome (IBS) is a common disorder that poses a management challenge. IBS with constipation as the dominant bowel habit is a common phenotype and features abdominal pain, infrequent bowel movements or difficult defecation, bloating and distention, as major symptoms. While laxatives increase stool frequency, they have little impact on other symptoms; prior, more specificall...
متن کاملbloating in irritable bowel syndrome
aim : the purpose of this study was to describe the occurrence of self report bloating and related factors in patients with irritable bowel syndrome (ibs). background : bloating symptoms are common in patients with ibs and have significant impact on normal daily function. patients and methods : this study was a community-based cross-sectional survey that conducted using a valid questionnaire ba...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Alimentary Pharmacology & Therapeutics
سال: 2021
ISSN: ['1365-2036', '0269-2813']
DOI: https://doi.org/10.1111/apt.16437